Abstract: Phosphodiesterase 10A (PDE10A) is a key enzyme of intracellular signal transduction which is involved in the regulation of neurotransmission. The molecular imaging of PDE10A by PET is expected to allow a better understanding of physiological and pathological processes related to PDE10A expression and function in the brain. The aim of this study was to develop a new 18
Introduction
3'5'-cyclic nucleotide phosphodiesterases (PDEs) catalyze the hydrolysis of the secondary messengers adenosine (cAMP) and guanosine monophosphate (cGMP). Thus PDEs terminate intracellular signaling cascades which are related to various physiological processes such as immune responses, cardiac and smooth muscle contraction, visual response, ion channel conductance, apoptosis, and growth control [1, 2] . Currently, 11 different families of PDEs are identified in mammals based on their primary amino acid and nucleotide sequences, regulatory properties, and substrate specificity [3] [4] [5] which hold great potential as drug targets for treatment of specific disease states [6] .
The development of inhibitors of PDE10A, the only known member of the PDE10 family, for neurological and psychiatric disorders makes this enzyme an interesting target for molecular imaging approaches. Although studies on expression and pharmacological intervention suggest a relation between PDE10A and striatal hypofunction, the particular pathways which link PDE10A function and neurotransmission are not completely understood. In the brain, PDE10A shows the most unique distinctive expression pattern of all PDEs with particularly high mRNA levels in caudate nucleus and nucleus accumbens, and much lower levels in other CNS regions [7] [8] [9] . The graduation in transcript expression closely resembles the distribution of the enzyme assessed in detail by immunohistochemistry in different mammalian species [7, 9, 10] . Within the striatal area, PDE10A was shown to be highly expressed by the GABAergic medium spiny projection neurons which represent ~90% of striatal neurons [10] . The primary association of PDE10A with the post-synaptic membrane, indicated by subcellular fractionation, appears to link PDE10A activity with the regulation of excitability of medium spiny neurons [11] . Outside the brain, the level of PDE10A transcripts correlates with PDE10A immunoreactivity as well. Although high expression in developing spermatocytes, thyroid and pituitary gland as well as striated and cardiac muscle was detected [6] [7] [8] 10] , the physiological function of PDE10A in these peripheral organs is not known.
In accordance with the high expression of PDE10A in striatal regions, the systemic administration of papaverine, a potent PDE10A inhibitor, induced a rapid increase in striatal levels of cGMP and cAMP in mice [12] and demonstrated a broad-spectrum efficacy in a range of antipsychotic models [12, 13] . Genetic deletion of PDE10A confirmed not only the involvement of this enzyme in the papaverine-mediated effects but has been reported to produce behavioral responses consistent with increased striatal output [14, 15] . Furthermore, alterations in the levels of PDE10A transcripts have been related to synaptic plasticity in the hippocampus following longterm potentiation [16] and in animal models of neurodegenerative disorders [17] .
These data form the basis for the hypothesis that PDE10A inhibitors will have potential for the treatment of neuropsychiatric disorders in humans that are correlated with striatal hypofunction such as schizophrenia, obsessive-compulsive disorders, Parkinson's disease, and Huntington's disease, and make PDE10A an interesting target for diagnostic and therapeutic monitoring by non-invasive imaging techniques such as positron emission tomography (PET). Therefore, numerous compounds which have been investigated concerning PDE10A inhibitory potency and behavioral impact [18] [19] [20] [21] [22] provide the current basis for the development of PDE10A targeting PET radiotracers.
Based on the PDE10A inhibitor papaverine (IC 50,PDE10A = 36 nM [12] ), Tu et al. successfully synthesized a carbon-11 labeled derivative (Figure 1, left) by methylation of the corresponding 4-phenolate with [ 11 C]methyl iodide [23] . Evaluation in vivo revealed an initially higher uptake in striatum in comparison to other brain regions. However, the very rapid clearance of the radioligand from the target region indicated [ 11 C]papaverine as not suitable for imaging of PDE10A. A major progress was made by the same group [24] and Plisson et al. [25] with the development of a carbon-11 labeled analogue of the highly potent and selective PDE10A inhibitor MP-10 (IC 50,PDE10A = 1.26 nM [13] , 0.37 nM [26] Figure 1,  right) , showing a maximum striatum-to-cerebellum ratio of 6.55 in rats and 1.5 to 2 in rhesus monkey at 30 min post-injection (p.i.) [24] . PET studies of [
11 C]MP-10 in pig and baboon revealed a specific, discrete, and reversible uptake in striatum with a peak at 1-2 min p.i. in porcine and at 40-60 min p.i. in nonhuman primate brain [25] . Radioligands investigated for PDE10A imaging and compound I, used as lead structure in this study.
Enabling high-resolution and long-term kinetic PET studies, 18 F-labeled MP-10 derivatives were developed as well. (Figure 1, right [29] ). This radioligand showed reversible and PDE10A specific striatal binding in biodistribution as well as in dynamic small-animal PET studies with a maximum striatum-to-cerebellum ratio of 4.60 at 30 min p.i. [29] . Target specific binding was confirmed by imaging in PDE10A knockout mice. Nevertheless, high plasma protein binding of [ 18 F]JNJ41510417, probably due to its high lipophilicity (JNJ41510417 c log P = 4.19 [29] ), and detrimental slow kinetics have been observed [28] . This result prompted the same group to synthesize the smaller and less lipophilic dimethylpyridine analogue [ 18 F]JNJ42259152
(JNJ42259152 c log P = 3.66, pIC 50,PDE10A = 8.8) [29, 30] Biodistribution studies in rats demonstrated a striatum-to-cerebellum ratio of 5.38 at 30 min p.i. Dynamic small-animal PET imaging in rat and monkey showed highly intensive, reversible and PDE10A selective uptake of the radioligand in striatum, with low background activity in cortical regions and cerebellum [30] . In consequence, a first human study is planned for PDE10A imaging with [ 18 F]JNJ42259152.
However, all MP-10 derived radioligands developed so far are adversely affected by metabolism [24, 25, [28] [29] [30] . Fast metabolism was observed in plasma of rats [28] , baboon [24, 25] and rhesus monkey [30] . The corresponding phenolic radioactive metabolite passed the blood-brain-barrier in rat and accumulated in the brain up to 15.9% [24] . In cerebellum up to 25.8% [28] and 53% [30] of metabolites were found at 60 min p.i.
As a structurally alternative approach and to possibly overcome the metabolic stability problem of the described PDE10A ligands, we intended to develop radioligands for PET imaging of PDE10A based on a 6,7-dimethoxyquinazoline (I, Figure 1 , center). Published by a Pfizer research group in 2007, this potent papaverine-related ligand inhibited PDE10A with a K i,PDE10A of 4 nM [31] . In this study we report on the development and investigation of a fluorine-18-labeled analogue. In a series of I-based compounds, the reference compound (R)-7-(2-fluoroethoxy)-6-methoxy-4-(3-(quinoxalin-2-yloxy) pyrrolidin-1-yl)quinazoline as well as two potential labeling precursors were synthesized in multi-step syntheses, and their PDE inhibitory potency was investigated [32] (data will be published in detail elsewhere). Since the 7-fluoroethoxyquinazoline derivative showed acceptable inhibitory potency with a K i,PDE10A of 53 nM and occurred as radiochemically most accessible, this compound was chosen for radiolabeling with fluorine-18 and subsequent evaluation in vitro and in vivo.
Results and Discussion

Radiosyntheses
Based on the 7-hydroxy precursor V, prepared via a 10-step synthesis [32] First labeling as well as 18 F-alkylation reactions were carried out in DMF at 110 °C. The reaction was accompanied by many side products and labeling efficiencies resulted in maximum 5% of [ 18 F]IV.
By changing the reaction medium to acetonitrile we achieved labeling efficiencies of 30%-45% for the 18 F-alkylation step. Only a limited number of radioactive by-products occurred, according to radio-TLC and radio-HPLC analyses. However, the purification of [ 18 F]IV was hindered due to lipophilic non-radioactive by-products. Even after solid phase extraction on alumina oxide and application of isocratic semi-preparative RP-HPLC (Figure 2A ), UV-active contents could not be satisfactorily removed from the final product. As result for the two-step radiosyntheses, within 3.5 to 4.5 h for the entire process [ 18 F]IV was obtained with radiochemical yields of 18%-29% (24% ± 6%, n = 4), but partially insufficient radiochemical purities of 92%-99% (95% ± 4%, n = 4). Purification of the crude [ 18 F]IV was successfully carried out by solid phase extraction on a C-18 or silica gel cartridge by means of acetonitrile (methanol could be used as well), followed by isocratic elution on semi-preparative RP-HPLC ( Figure 2B ). Formulation of the final product for biological testing was done by solvent exchange on a C-18 cartridge, removal of the organic eluent (acetonitrile, ethanol or methanol) and dissolution in physiological saline. Following this process, we obtained the radioligand [ 18 F]IV in radiochemical yields of 17%-40% (25% ± 9%, n = 10) within 3 to 4 h, with high chemical and radiochemical purities of ≥99%, and high specific activities in the range from 110 to 1,100 GBq/μmol.
Lipophilicity and Radioligand Stability in Vitro
To provide an indication of unspecific binding and blood-brain barrier permeability of [
we calculated logarithmic distribution coefficients log D. The calculation was done with ACD/LogD (version 4.56, Advanced Chemistry Development Inc., Toronto, Canada) and MarvinSketch (ChemAxon Ltd., Budapest, Hungary). Values, given in Table 1 , reached from a log D 7.2 value of 2.27, which is, beside other criteria, pointing to an adequate brain penetration and optimum target to non-target ratio [35] , up to log D 7.0-7.4 = 3.52, indicating a high lipophilicity and possibly efficient brain uptake, but high unspecific binding as well. experimentally, under physiological pH conditions in solid-liquid phase systems via retention on RP-HPLC, and in liquid-liquid phase systems by conventional shake-flask method. In three n-octanol/aqueous buffer solution systems at a pH range of 7.2 to 7.4, log D values of up to 2.73 were obtained for the radioligand (Table 1) . With a retention time based capacity factor k in relation to those of standard substances [36] , lipophilicity of IV was determined on two reversed phase/neutral buffered eluent systems with log D = 2.63. All in one, an experimental log D 7.0-7.4 value of ~2.7 promised a good potential for brain uptake of respectively, and showed a sufficient stability with 97% in physiological phosphate-saline (pH 7.2), verified by radio-TLC on silica gel and alumina oxide plates. For formulation and storage, radioligand stability in acetonitrile (98%, 1 h, 80 °C) and in ethanol (98%, 1 h, 80 °C; ≥99%, 1.5 h, 40 °C) was proven.
PDE10A Affinity and Selectivity
The dissociation constant K D of [ 18 F]IV was determined in homologous competitive binding experiments by nonlinear regression analysis [37] . Cell membrane homogenates from PDE10A-transfected SF21 cells (100 µg protein/mL incubation volume) were incubated with solutions of six concentrations of IV (working concentration 10 pM-10 µM), each spiked with a fixed concentration of H]-cAMP revealed inhibitory potency of IV not only towards PDE10A (IC 50 = 105 nM) but also towards PDE3A (IC 50 = 88.7 nM) and PDE4A (IC 50 = 562 nM), while the enzymatic activity of the PDEs 1B, 2A, 5A, 6, 7B, 8A, 9A, and 11A was not affected (IC 50 > 1000 nM) [32] . Therefore, the resultant functional selectivity is moderate. Nevertheless, the distinctive expression of PDE10A with levels of mRNA much higher than that of PDE3A or PDE4A in striatum [8] was assumed to allow the detection of PDE10A expression by [ 18 F]IV. Contrary to the numerous investigations regarding the inhibitory potency of PDE10A ligands [18] [19] [20] [21] [22] , so far no data have been published concerning the affinity of PDE10A inhibitors. Although the available data on PDE10A transcript and protein expression did not allow a pre-estimation of the B max value of the target, with respect to the sub-nanomolar to nanomolar affinity values of successful PET-radioligands in neuroimaging [38] , we assumed the nanomolar affinity of 
Autoradiography in Vitro
In vitro co-incubation of rat brain slices with [ with an accumulation in PDE10A specific brain regions like caudate putamen, nucleus accumbens, substantia nigra, olfactory tubercle and cerebellum ( Figure 3A,B) . This pattern corresponds with the immunohistochemical localization of PDE10A in rat brain described in Seeger et al. [9] . However, [ 18 F]IV binding was not completely inhibited by the highly PDE10A specific MP-10 ( Figure 3C ). [32] ) in association with a high expression of PDE3A mRNA in the olfactory bulb, cerebral cortex, cerebellum and the pontine nuclei of the rat brain, described by Reinhardt et al. [39] . Notably, Lakicz et al. [8] did not detect expression of PDE3A/B mRNA in human brain. Therefore, species-specific patterns of PDE expression have to be considered in the development of PDE10A targeting PET ligands based on the herein reported quinazoline structures. Furthermore, computer-assisted prediction of bioactivity of IV using Molinformation Cheminformatics software (Molinspiration Cheminformatics, Slovensky Grob, Slovak Republic) indicate high activity of compound IV as kinase inhibitor (score 0.92) and moderate activity as general enzyme inhibitor (score 0.57). Therefore, future work on structurally related PDE10 targeting ligands will have to focus on target selectivity in terms of kinase inhibitory potency.
Radioligand Stability in Vivo
The metabolic fate of [ 18 F]IV was investigated in brain, plasma and urine samples of CD1-mice at 30 and 60 min p.i. Proteins were precipitated with acetonitrile and extraction efficiencies of 96.4% for brain homogenate, 90.2% for plasma and 89.4% for urine were obtained, indicating sufficient recovery rates. The supernatants of each material were analyzed by radio-TLC and analytical radio-HPLC, whereof two representative chromatograms are given in Figure 4 . F]IV and the single plasma-and brain-related radiometabolite accounted for only ~1% of the total radioactivity in urine, further radiometabolites were detected. The main three of them represent 11%, 12% and 44% of the total radioactivity. In contrast to brain and plasma samples, in urine free [ 18 F]fluoride could be detected, although at a low level of only ~5% of total radioactivity.
Biodistribution and Specificity in Vivo
The organ distribution of [ 18 F]IV after i.v. injection was investigated in female CD-1 mice.
Time-activity data for 18 F corresponding uptake in peripheral organs, in the brain and in particular in the striatum at 5, 30, 60 and 120 min p.i. are presented in Table 2 . Furthermore, a major part of the radiotracer is excreted hepatobiliary, as indicated by the radioactivity uptake in liver (20.5% ID/g at 5 min p.i. to 7.05% ID/g at 120 min p.i.) and intestine (13.5% ID/g and 42.8% ID/g, 5 and 60 min p.i., respectively). The high accumulation of radioactivity in adrenals of up to 48.5% ID/g at 30 min p.i. points to the involvement of cytochrome P450 oxygenases in radiotracer metabolism, as these enzymes are highly expressed in adrenals [40] . The results of the blocking experiments, performed by pre-injection of the potent and selective PDE10A inhibitor MP-10 or of compound I indicated low specificity of [ 18 F]IV binding in the brain and other tissues because no significant changes in the amount of accumulated radioactivity could be determined in all organs known to express PDE10A (p > 0.05). The observed slightly increase in the uptake of radioactivity in most organs might be caused by an increase in the free fraction of [ 18 F]IV in plasma or changes in physiological parameters such as blood flow due to high concentrations of the blocking compounds.
Autoradiography ex Vivo
To determine the regional distribution of [ 18 F]IV in the brain in vivo, we also performed ex vivo autoradiography. In CD-1 mice brain, heterogeneous distribution of radioactivity was noticed at 30 min after [ 18 F]IV injection ( Figure 5 ), but the localization of radioligand did neither correlate with the spatial distribution of PDE10A in the brain known from immunohistochemical [9] and in vivo PET studies [25] nor with the pattern of 
Experimental Section
General
No Processed TLC plates and organ sections were exposed to 18 F-sensitive storage phosphor screens (BAS-TR2025, FUJIFILM Co., Tokyo, Japan), and image plates were analyzed using a bioimaging analyzer system (BAS-1800 II, BASReader 2.26 Beta and AIDA 2.31 Image Analyzer software; Raytest GmbH, Straubenhardt, Germany, and FUJIFILM Co., Tokyo, Japan).
In vivo studies were carried out in 3-months-old female CD-1 mice (20-25 g). Animals were obtained from the Medizinisch-Experimentelles Zentrum, Universität Leipzig, maintained on a 12 h light-dark cycle, and habituated for at least two days before experiments. All procedures involving animals were approved by the respective State Animal Care and Use Committee and conducted in accordance with the German Law for the Protection of Animals.
Radiochemistry
Two-Step Radiosynthesis of (R)-7-(2-[
18 F]Fluoroethoxy)-6-methoxy-4-(3-(quinoxalin-2-yloxy)
A representative procedure is given as follows. and acetonitrile (1 mL) in a 10 mL conical vessel, equipped with magnetic stirrer, septum, as well as vacuum and inert gas access. This mixture was azeotropically dried according to previously described protocols [41, 42] , resulting in the K[ In a 2 mL reaction vessel, equipped with magnetic stirrer, septum and inert gas access, (R)-7-hydroxy-6-methoxy-4-[3-(quinoxalin-2-yloxy)pyrrolidine-1-yl]quinazoline (V, 4.0 mg, 0.01 mmol) in acetonitrile (1 mL) were stirred with Kryptofix ® (1.90 mg, 0.01 mmol) and K 2 CO 3 (0.35 mg, 0.005 mmol) at 60 °C, using a heating block. After 2 h, the acetonitrile was carefully evaporated to dryness under inert gas and the mixture dissolved in anhydrous acetonitrile (1 mL). At room temperature, the yellow phenolate-containing solution (500 μL, 0.005 mmol) was added to a solution of [ and then centrifuged at 6000 rpm (21 °C, 5 min; EBA 12R, Andreas Hettich GmbH & Co. KG, Tuttlingen, Germany). Aliquots of 1 mL of the n-octanol phase and 1 mL of the aqueous phase were transferred into separate sample tubes with care. Radioactivity of these samples was quantified using a calibrated γ-counter (Wallac WIZARD, Perkin Elmer, Waltham, MA, USA). The procedure mentioned above was repeated for each serial 3-4 times using 1 mL of the n-octanol phase collected after each Referring to an OECD guideline [36] and using a series of reference compounds (nitrobenzene, p-nitrophenol, benzene, toluene, chlorobenzene, benzophenone, naphthalene, 1,4-dibromobenzene, biphenyl, diphenylether, 1,4-diiodobenzene) with known log P OW values comprised between 1.89 and 4.64, retention times were determined on two reversed phase columns (Multospher 120 RP-18 AQ, 250 mm × 4.6 mm, 5 μm, CS-Chromatographie Service GmbH, Langerwehe, Germany; SupelcosilTM ABZ + Plus, 250 × 4 mm, 5 μm, Supelco, Bellefonte, PA, USA). On an 1100 HPLC ChemStation (Agilent Technologies, Santa Clara, CA, USA) using a gradient (5% to 80% MeCN/H 2 O and 20 mM NH 4 OAc over 65 min, pH = 7.0, flow rate 1 mL/min, λ = 254 nm), reference compound IV (t R,IV@Multospher = 43.7, t R,IV@Supelcosil = 27.9 min) as well as standard compounds have been eluted with n ≥ 3 on each column. Dead times t 0 were determined by retention of thiourea. Corresponding capacity factors k for all compounds were calculated and plotted as log k versus log P of the standard compounds, affording calibration curves (Microcal TM Origin 6.0, Microcal Software, Inc., Northhampton, MA, USA). The regression equations were then used to calculate the log D 7.0 values of IV via its corresponding log k (values are given in Table 1 ).
In Vitro Characterization
PDE10A Affinity
Crude membrane homogenates isolated from PDE10A-transfected SF21 cells were obtained from Biocrea GmbH, Radebeul, Germany [43] . For competitive radioligand displacement experiments (n = 2), the membrane preparations were diluted with incubation buffer (50 mM Tris-HCl, pH 7.4 at room temperature, 5 mM MgCl 2 ) and re-homogenized by passing through a 27-gauge needle. The protein (100 µg) was incubated with 0.05-0.1 nM of [ 18 F]IV and different concentrations of IV (10 pM-1 µM), diluted from a 10 mM stock in DMSO, at a final volume of 1 mL. Nonspecific binding was determined in the presence of 10 µM of I, and control incubation was carried out accordingly using crude membrane preparations obtained from non-transfected SF21 cells. Incubation at room temperature was terminated after 120 min by rapid filtration (Brandel 48-channel harvester; Biomedical Research and Development Lab. Inc., Gaithersburg, MD, USA) on Whatman GF/B glass-fiber filters, pre-soaked for 90 min in 0.3% polyethylenimine (Sigma, Deisenhofen, Germany), followed by washing four times with 4 mL of ice-cold wash buffer (50 mM Tris-HCl, pH 7.4 at 4 °C). Filter-bound radioactivity was quantified using a calibrated γ-counter (Wallac WIZARD, Perkin Elmer, Waltham, MA, USA).
Data Analysis
Each experiment was carried out in triplicate. The binding parameter IC 50 was estimated using iterative non-linear curve fitting. were analyzed using the BAS-1800 II system (see above). screens for 60 min, image plates were analyzed using a bioimaging analyzer system (see above).
Biodistribution and Metabolism Studies in Mice
Conclusions
In our efforts to develop a PET ligand for imaging PDE10A in vivo based on a known structure I, we successfully synthesized a first 
